Curated News
By: NewsRamp Editorial Staff
October 01, 2026
Helus Pharma Completes Name Change from Cybin Inc.
TLDR
- Helus Pharma renamed from Cybin, shares still trade as HELP on Nasdaq and Cboe, positioning for commercial launch.
- Cybin legally changed its name to Helus Pharma on Oct 1, 2026, following shareholder approval and a January business name adoption.
- Helus Pharma develops serotonergic agonists to treat depression and anxiety, aiming to heal minds and improve mental health outcomes.
- Cybin became Helus Pharma, keeping HELP ticker, as it advances HLP003 for major depression with FDA Breakthrough Therapy Designation.
Impact - Why it Matters
This name change signals Helus Pharma's evolution from a clinical-stage discovery company to a commercial-ready pharmaceutical firm, potentially accelerating the path to market for its novel serotonergic agonists. With HLP003 in Phase 3 for major depressive disorder and FDA Breakthrough Therapy Designation, the company is positioning itself as a leader in mental health therapeutics. For investors, the rebranding may enhance brand recognition and reflect growing maturity, while patients suffering from depression and anxiety could benefit from a new class of treatments designed to promote neuroplasticity and provide durable improvements. The move also underscores the increasing convergence of psychedelic-inspired science and mainstream pharmaceutical development.
Summary
Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists ("NSAs"), has officially changed its legal name from Cybin Inc. to Helus Pharma Inc., effective Oct. 1, 2026. Shareholders approved the change at the company's Sept. 22 annual and special meeting, following the adoption of the Helus Pharma business name in January. The rebrand reflects the company's anticipated transition from a clinical-stage discovery and development company to a commercial-ready pharmaceutical company, with its common shares continuing to trade under the ticker HELP on the Nasdaq Global Market and Cboe Canada, and no action required by existing shareholders.
Helus Pharma, founded in 2019, is committed to helping minds heal by developing proprietary NSAs—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company's lead candidate, HLP003, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Another proprietary NSA, HLP004, is in Phase 2 for generalized anxiety disorder. With class-leading data, Helus Pharma aims to improve the treatment landscape for depression, anxiety, and other mental health conditions. The Company operates in Canada, the United States, the United Kingdom, and Ireland. For more information, visit www.helus.com or follow the team on X, LinkedIn, YouTube, and Instagram. Helus Pharma(TM) is a trademark of Cybin Corp.
The announcement was disseminated on behalf of Helus Pharma and may include paid advertising. The latest news and updates relating to HELP are available in the company's newsroom at https://ibn.fm/HELP. MissionIR is a specialized communications platform focused on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Helus Pharma Completes Name Change from Cybin Inc.
